MNMD Insider Trading

Insider Ownership Percentage: 2.26%
Insider Buying (Last 12 Months): $24,085.00
Insider Selling (Last 12 Months): $749,479.40

Mind Medicine (MindMed) Insider Trading History Chart

This chart shows the insider buying and selling history at Mind Medicine (MindMed) by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Mind Medicine (MindMed) Share Price & Price History

Current Price: $5.43
Price Change: Price Increase of +0.29 (5.64%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for MNMD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$5.43Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Mind Medicine (MindMed) (NASDAQ:MNMD)

27.91% of Mind Medicine (MindMed) stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNMD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$42kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal InflowsTotal Outflows
Mind Medicine (MindMed) logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More on Mind Medicine (MindMed)

Today's Range

Now: $5.43
Low: $5.05
High: $5.44

50 Day Range

MA: $6.84
Low: $4.89
High: $9.89

52 Week Range

Now: $5.43
Low: $4.70
High: $10.47

Volume

604,202 shs

Average Volume

1,401,941 shs

Market Capitalization

$409.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.54

Who are the company insiders with the largest holdings of Mind Medicine (MindMed)?

Mind Medicine (MindMed)'s top insider investors include:
  1. Robert Barrow (CEO)
  2. Daniel Karlin (Insider)
  3. Dan Karlin (Insider)
  4. Schond L Greenway (CFO)
  5. Carrie Liao (CAO)
  6. David W Gryska (Director)
Learn More about top insider investors at Mind Medicine (MindMed).

Who are the major institutional investors of Mind Medicine (MindMed)?

Mind Medicine (MindMed)'s top institutional investors include:
  1. Rhumbline Advisers — 0.14%
Learn More about top institutional investors of Mind Medicine (MindMed) stock.

Which major investors are buying Mind Medicine (MindMed) stock?

Within the last quarter, MNMD stock was acquired by institutional investors including:
  1. Rhumbline Advisers
In the previous year, these company insiders have bought Mind Medicine (MindMed) stock:
  1. Robert Barrow (CEO)
  2. Daniel Karlin (Insider)
Learn More investors buying Mind Medicine (MindMed) stock.